AlphAIalphai — Financial news for AI agents
investing.comAUG 252 min read$OMER

Omeros VP of finance David Borges sells $206,804 in shares

Omeros Corp's (NASDAQ:OMER) VP of Finance, David Borges, sold 10,906 shares for $206,804 after exercising options. Shares were sold at $18.95-$19.10, with options exercised at $2.94-$3.93. Omeros reported Q2 earnings of $0.02 per share, beating estimates, and revenue of $28.5M, also exceeding forecasts, driven by its drug YARTEMLEA.

Original reporting
investing.com
Published Aug 25, 2026, 11:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 5:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$OMER
Neutral
medium confidence
Mentioned
$OMER
Relevance
5/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$OMERNeutralLow
01

Why it matters

Earnings beat supports bullish view, while insider sale adds a neutral counterbalance.

02

Market read

Earnings beat may drive short‑term upside; insider sale introduces modest downside risk.

03

What to watch

Strong Q2 earnings beat could offset any negative sentiment from the sale.

Relevance 5/10Novelty 5/10Timing: post‑market Aug 25

Background

Omeros Corp reported Q2 earnings that beat expectations, driven by YARTEMLEA launch.

Company-level read

Ticker impact

$OMERNeutralMedium confidence
Context

VP of finance David Borges sold $206,804 of OMER shares via a Rule 10b5-1 plan, disclosed in a Form 4 filing.

Expected impact

Potential slight downward pressure in near term.

Evidence & confidence

Sale amount is small relative to market cap; typical for scheduled plan, unlikely to move price significantly.

Market effects

Sector

Minimal impact on biotech sector; insider sales are routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not imply negative outlook.

Key entities

  • Company
    Omeros Corp

    Biotech firm (NASDAQ:OMER) reporting earnings and insider sale.

  • Executive
    David J. Borges

    VP of Finance & CAO, insider selling shares.

Read at source← All news

Related articles

AUG 20
$OMERHighAI 8/10

Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.

fool.com3 min
AUG 14
$OMERMed

Omeros Corporation Q2 2026 Earnings Call Summary

Omeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.

yahoo.com5 min
AUG 13
$OMERHighAI 9/10

Why is Omeros stock surging today?

Omeros (OMER) shares rose about 17% in pre-open after the company reported Q2 2026 results. Adjusted EPS was $0.02 versus a consensus $0.25 loss, and revenue was $28.5M versus $12.67M expected. YARTEMLEA sales were $32.2M gross, and Omeros reported GAAP net income of $13.2M and first positive operating cash flow.

investing.com4 min
AUG 12
$OMERMed

OMEROS CORP (OMER): Results of Operations and Financial Condition

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 12, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second q

SEC EDGAR 8-K7 min
JUL 28
$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

rttnews.com6 min